Current management practices for acromegaly: An international survey

Pituitary

Volumn 14, Issue 2, 2011, Pages 125-133

  Giustina, A ^a   Bronstein, M D ^b   Casanueva, F F ^c   Chanson, P ^d   Ghigo, E ^e   Ho, K K Y ^f   Klibanski, A ^g   Lamberts, S ^h   Trainer, P ⁱ   Melmed, S ^j  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITY OF TURIN   (Italy)

^f GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

^j CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

Acromegaly; Growth hormone; Insulin like growth factor I; Pegvisomant; Questionnaire; Somatostatin analogs

Indexed keywords

GROWTH HORMONE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR;

ACROMEGALY; ARTICLE; CHEMICAL ANALYSIS; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; GENERAL PRACTITIONER; HUMAN; MICROADENOMA; MONOTHERAPY; NEUROSURGERY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PATIENT REFERRAL; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT INDICATION;

ACROMEGALY; AUSTRALIA; BRAZIL; CANADA; CHINA; DATA COLLECTION; ENDOCRINOLOGY; EUROPE; HUMANS; INTERNATIONALITY; NEUROSURGERY; NEW ZEALAND; PHYSICIANS, PRIMARY CARE; POSTOPERATIVE PERIOD; PROFESSIONAL PRACTICE; TREATMENT OUTCOME; UNITED STATES;

EID: 79958150259     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-010-0269-9     Document Type: Article

References (34)

1. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189-3202
2. Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. Pituitary 2:29-41
3. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769-4775 (Pubitemid 44917305)
4. Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK (2008) High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 69:432-435
5. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674 (Pubitemid 38269875)
6. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P (2007) Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 92:1743-1747 (Pubitemid 46997181)
7. Davi MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, Francia G (2008) Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 159:533-540
8. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94:1500-1508
9. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737-740 (Pubitemid 43020222)
10. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517
11. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529 (Pubitemid 32273628)
12. Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S (2008) Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 31:820-838
13. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S (2003) Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242-1247 (Pubitemid 38324744)
14. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141-3148
15. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
16. Giustina A, Mancini T, Boscani PF, de Menis E, degli Uberti E, Ghigo E, Martino E, Minuto F, Colao A (2008) Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) study. J Endocrinol Invest 31:731-738
17. Nachtigall L, Delgado A, Swearingen B, Lee H, Zerikly R, Klibanski A (2008) Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 93:2035-2041 (Pubitemid 351831512)
18. Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94:523-527
19. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558-2573
20. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL (2002) Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87:3537-3542
21. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN (2003) Basal and glucose-suppressed GH levels less than 1 microg/l in newly diagnosed acromegaly. Pituitary 6:175-180 (Pubitemid 39127616)
22. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C (2002) Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56:65-71 (Pubitemid 34107323)
23. Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, de Marinis L, Degli Uberti E, Bogazzi F, Mazziotti G, Minuto F, Montini M, Ghigo E (2009) High-dose intramuscular octreo-tide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 161:331-338
24. Ahmed E, Stratton P, Adams W (1999) Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 50:561-567
25. Bates PR, Carson MN, Trainer PJ, Wass JA (2008) Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol (Oxf) 68:136-142 (Pubitemid 350243493)
26. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613-1617 (Pubitemid 38507910)
27. Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94:2015-2022
28. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90:4081-4086 (Pubitemid 41058176)
29. Puder JJ, Nilavar S, Post KD, Freda PU (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90:1972-1978 (Pubitemid 40590060)
30. Colao A, Arnaldi G, Beck-Peccoz P, Cannavo S, Cozzi R, degli Uberti E, De Marinis L, De Menis E, Ferone D, Gasco V, Giustina A, Grottoli S, Lombardi G, Maffei P, Martino E, Minuto F, Pivonello R, Ghigo E (2007) Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest 30:693-699
31. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177 (Pubitemid 30211048)
32. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
33. Herman-Bonert VS, Zib K, Scarlett JA, Melmed S (2000) Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 85:2958-2961 (Pubitemid 32269181)
34. De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A, Giustina A (2007) Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary 10:227-232 (Pubitemid 350055033)